NCT01247194 - A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions

Chronic Genotype 1 Hepatitis C Virus Infection

Interventions

DRUG

PPI-461

capsule, oral, once daily for 3 days

DRUG

Placebo

capsules, oral, once daily for 3 days

Trial Locations (11)

Local institution, San Francisco

Local Institution, Sacramento

Local institution, Aarhus

Local institution, Copenhagen

Local institution, Herlev

Local institution, Hvidovre

Local institution, Kolding

Local institution, Odense

Local institution, London

Local institution, London

Local institution, London